Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats

Cancer Immunology, Immunotherapy

Volumn 54, Issue 4, 2005, Pages 337-344

  Goetz, Claudia Maria ^a   Rachinger, Walter ^a   Decker, Markus ^a   Gildehaus, Franz Josef ^a   Stocker, Susanne ^a   Jung, Gundram ^b   Tatsch, Klaus ^a   Tonn, Jörg Christian ^a   Reulen, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

C6 glioma; Distribution; Fragments; Radioimmunotherapy; Tenascin

Indexed keywords

IODINE 125; TENASCIN;

ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; AUTORADIOGRAPHY; CANCER SURGERY; CELL MIGRATION; CONTROLLED STUDY; GLIOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RAT; REDUCTION; VELOCITY;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTORADIOGRAPHY; BRAIN NEOPLASMS; GLIOMA; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRALESIONAL; IODINE RADIOISOTOPES; RADIOIMMUNOTHERAPY; RATS; RATS, WISTAR; TENASCIN;

EID: 13744262670     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0608-7     Document Type: Article

References (45)

1. Aaslid R, Groger U, Patlak CS, Fenstermacher JD, Huber P, Reulen HJ (1990) Fluid flow rates in human peritumoural oedema. Acta Neurochir Suppl (Wien) 51:152
2. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45
3. Bashir R, Hochberg F, Oot R (1988) Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23:27
4. Behr TM, Wormann B, Gramatzki M, Riggert J, Gratz S, Behe M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W (1999) Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 5:3304s
5. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 52:121
6. Boskovitz A, Akabani GH, Pegram CN, Bigner DD, Zalutsky MR (2004) Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nucl Med Biol 31:345
7. Brady LW, Markoe AM, Woo DV, Rackover MA, Koprowski H, Steplewski Z, Peyster RG (1990) Iodine 125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. A pilot study. J Neurosurg Sci 34:243
8. Breyer R, Hussein S, Radu DL, Putz KM, Gunia S, Hecker H, Samii M, Walter GF, Stan AC (2000) Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J Neurosurg 92:140
9. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L (1999) Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 154:1345
10. Castellani P, Dorcaratto A, Siri A, Zardi L, Viale GL (1995) Tenascin distribution in human brain tumours. Acta Neurochir (Wien) 136:44
11. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, Gebarski SS, Sandler HM (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635
12. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, Zalutsky MR, Bigner DD (2000) Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862
13. Colapinto EV, Lee YS, Humphrey PA, Zalutsky MR, Friedman HS, Bullard DE, Bigner DD (1988) The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. Br J Neurosurg 2:179
14. 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. Cancer Res 50:1822
15. 125I-MAb 425 in a human glioma xenograft model: effect of chloroquine. Hybridoma 16:93
16. Emrich JG, Brady LW, Quang TS, Class R, Miyamoto C, Black P, Rodeck U (2002) Radioiodinated (1-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol 25:541
17. Fisher B, Won M, MacDonald D, Johnson DW, Roa W (2002) Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53:980
18. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL (2002) A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncology 4:261
19. Gildehaus F-J, Rachinger W, Decker M, Stocker S, Goetz C, Poepperl G, Tatsch K, Reulen H J (2003) Migration properties of a radiolabeled intact Antibody and Fab-Fragment after locoregional application in C6-glioma of the rat. J Nucl Med 44 [suppl]:36P
20. Goetz C, Riva P, Tatsch K, Gildehaus F-J, Reulen HJ (2003) Radioimmunotherapy in selected patients with malignant glioma, survival times and side effects. J Neurooncol 62:321
21. Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693
22. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207
23. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH (2002) Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 98:362
24. Jansen EP, Dewit LG, van Herk M, Bartelink H (2000) Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 56:151
25. Jung G, Freimann U, Von Marschall Z, Reisfeld RA, Wilmanns W (1991) Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 21:2431
26. Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, Phillips P, Herman T, Gerber M (2002) Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol 20:3149
27. Laboratory of Neuro Imaging (2004) Rat atlas. LONI, UCLA, Los Angeles. http://www.loni.ucla.edu/Research/Atlases/Rat-Atlas.html. Cited 13 September 2004
28. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S (2003) Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98:2430
29. Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63:218
30. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348
31. 131I-labelled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV). Nuklearmedizin 41:120
32. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389
33. Reulen HJ, Graham R, Spatz M, Klatzo I (1977) Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. J Neurosurg 46:24
34. Reulen HJ, Graber S, Huber P, Ito U (1988) Factors affecting the extension of peritumoural brain oedema. A CT-study. Acta Neurochir (Wien) 95:19
35. Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, Giuliani G, Casi M (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 80:2733
36. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-phase I and II study. Acta Oncol 38:351
37. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M (2000) Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 27:601
38. Schold SC Jr, Zalutsky MR, Coleman RE, Glantz MJ, Friedman AH, Jaszczak RJ, Bigner SH, Bigner DD (1993) Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol 28:488
39. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD (1992) Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36:41
40. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405
41. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM (1990) Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 31:508
42. Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Pluckthun A (2001) Tumor targeting of mono-, di-, and tetravalent anti-p185 (HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem 276:14385
43. Zagzag D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, Cohen H, Grumet M, Greco MA (1995) Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 55:907
44. Zalutsky MR, Moseley RP, Benjamin JC, Colapinto EV, Fuller GN, Coakham HP, Bigner DD (1990) Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 50:4105
45. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody fragments in nude mice. Cancer Res 47:1691